Maridebart Cafraglutide
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen · Phase 3 · Recruiting · Enrollment 950
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Maridebart Cafraglutide Low Dose Q4W | n/r | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide Medium Dose Q4W | n/r | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide Medium dose Q8W | n/r | n/r | n/r | n/r | n/r |
| Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial) | n/r | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide High Dose Q4W | n/r | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide High Dose Q8W | n/r | n/r | n/r | n/r | n/r |
| Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial) | n/r | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial) | n/r | n/r | n/r | n/r | n/r |
| Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial) | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.